Key Developments: Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,752JPY
1:43am EDT
Price Change (% chg)

¥-16 (-0.33%)
Prev Close
¥4,768
Open
¥4,736
Day's High
¥4,780
Day's Low
¥4,724
Volume
1,659,400
Avg. Vol
1,918,339
52-wk High
¥5,170
52-wk Low
¥4,396

Search Stocks

Latest Key Developments (Source: Significant Developments)

Seattle Genetics and Takeda announce positive data from phase 3 AETHERA clinical trial of ADCETRIS for consolidation in post-transplant Hodgkin Lymphoma
Monday, 29 Sep 2014 06:45am EDT 

Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd:Says that patients with Hodgkin lymphoma (HL) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) lived significantly longer without disease progression compared to patients who received placebo.Phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse.ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL.ADCETRIS has been approved in more than 45 countries for the treatment of relapsed HL and systemic anaplastic large cell lymphoma (sALCL).ADCETRIS is not approved in the AETHERA treatment setting.  Full Article

BioMotiv and Takeda Pharmaceutical enter into strategic partnership
Thursday, 25 Sep 2014 01:15pm EDT 

Takeda Pharmaceutical Co Ltd:Says Takeda has made a strategic investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations.Says Initial investment is $25 mln over five years.Says investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of Immunology & Inflammation and Cardio-metabolic Diseases.  Full Article

Takeda and Orexigen announce FDA approval of Contrave (naltrexone HCI and bupropion HCI) extended-release tablets for chronic weight management
Thursday, 11 Sep 2014 07:00am EDT 

Orexigen Therapeutics Inc and Takeda Pharmaceuticals U.S.A., Inc:U.S. FDA approves Contrave(naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.Takeda is committed to providing patients with obesity with treatment options that help address their needs, and the company is planning to commercially launch Contrave in the fall of 2014.Effect of Contrave on cardiovascular morbidity and mortality has not been established.  Full Article

Takeda Pharmaceutical Co Ltd announces jury verdict
Wednesday, 3 Sep 2014 08:30pm EDT 

Takeda Pharmaceutical Co Ltd:Takeda Pharmaceutical and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. announced that judgment was entered on the jury verdict that was returned on April 7, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al.The court has yet to rule on Takeda and Eli Lilly & Co.’s post-trial motion for a new trial, or alternatively, a significantly reduced punitive damage award.Takeda has prevailed in all five ACTOS (pioglitazone HCl) cases tried in state courts and The Allen case is the only case to reach trial in the multidistrict litigation pending in the federal courts.  Full Article

Takeda Pharmaceutical Co Ltd transfers Nippon Rinsho to Medical Tribune, Inc.
Wednesday, 3 Sep 2014 02:30am EDT 

Takeda Pharmaceutical Co Ltd:Sold all shares of Nippon Rinsho to Medical Tribune, Inc.No further details disclosed.  Full Article

R&I affirms Takeda Pharmaceutical Co Ltd's rating at "AA+" and announces negative outlook
Friday, 29 Aug 2014 02:11am EDT 

Takeda Pharmaceutical Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA+".Rating outlook negative, changed from stable.  Full Article

Takeda Pharmaceutical Co Ltd reaffirms FY 2015 outlook - Conference Call
Friday, 1 Aug 2014 05:00pm EDT 

Takeda Pharmaceutical Co Ltd:Says it is maintaining FY 2015 sales and earning guidance.Says it is confident of reaching guidance of 2- 4 pct probably for sales and flat to slightly declining in core earning for FY 2015.Reported revenue of 1,691 bln yen, EPS of 135.10 yen, net income of 100.10 bln yen in FY 2014.FY 2015 revenue of 1,725 bln yen, EPS of 125.20 yen, net income of 106.66 bln yen - Thomson Reuters I/B/E/S.  Full Article

Takeda Pharmaceutical Co Ltd announces conclusion of cooperative commercialization regarding product SELTOUCH
Tuesday, 22 Jul 2014 03:00am EDT 

Takeda Pharmaceutical Co Ltd:Pfizer Japan Inc.,Takeda Pharmaceutical Company Limited and ASKA Pharmaceutical Co., Ltd announced that they have reached an agreement to conclude their contracts regarding the product SELTOUCH® (“SELTOUCH”, generic name: felbinac), effective Sep. 30.Says distribution and marketing activities for both poultice formulation and tape formulation of Pfizer's transdermal absorption-type analgesic and anti-inflammatory agent SELTOUCH (SELTOUCH PAP 70, SELTOUCH PAP 140, and SELTOUCH TAPE 70) by Takeda and ASKA will be concluded, effective Oct. 1.Pfizer will conduct the distribution and marketing activities for this product.  Full Article

Takeda Pharmaceutical Co announces termination of Orteronel (TAK-700) development for prostate cancer in Japan, U.S.A. and Europe
Thursday, 19 Jun 2014 02:00am EDT 

Takeda Pharmaceutical Co Ltd:Voluntarily decided to end the development program for orteronel (TAK-700) for prostate cancer.Decision follows the results of two Phase 3 clinical trials in metastatic, castration resistant prostate cancer.Studies found while orteronel plus prednisone could extend the time patients lived before their cancer progressed, it did not extend overall survival in these patients.Says the drug has not demonstrated a clinical profile sufficient to move forward in mCRPC, given the availability of other therapies.  Full Article

Takeda Pharmaceutical Co Ltd and H. Lundbeck A/S presents data on new CONNECT study measures of cognitive performance in adult patients treated with Brintellix
Monday, 16 Jun 2014 06:30am EDT 

Takeda Pharmaceutical Co Ltd and H. Lundbeck A/S:Results from CONNECT, new study that evaluated the effect of Brintellix 10-20 mg/d on aspects of cognitive function.Says using an objective neuropsychological test (the Digit Symbol Substitution Test or DSST) associated with executive function, processing speed and attention, in adults with major depressive disorder (MDD).Says data will be presented as a late-breaker poster at the 29thInternational College of Neuropsychopharmacology (CINP) World Congress in Vancouver, Canada.In this study, adult patients with MDD, a MADRS total score >/= 26, and self-reported cognitive dysfunction were randomized to flexibly dosed Brintellix 10-20 mg/d (n=198), placebo (n=194), or the active reference (duloxetine 60 mg/d; n=210) included to demonstrate assay sensitivity for depression.Primary endpoint was change from baseline to Week 8 on the DSST (ANCOVA).Key secondary endpoints, patient-reported Perceived Deficits Questionnaire (PDQ) attention/concentration and planning/organization subscore and Clinical Global Impressions - Global Improvement Scale (CGI-I) at Week 8 were analyzed in pre-specified testing sequence using full-analysis set (FAS).Additional endpoints included MADRS total score to confirm efficacy on the overall symptoms of depression, and a prespecified path analysis to detect direct vs. indirect effects on cognition.  Full Article

Photo

Seattle Genetics and Takeda's cancer drug meets main trial goal

- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

Search Stocks